Iambic Therapeutics IAM
NASDAQ IAM
$15.05 +0.27 (+1.83%)
As of: Nov 11, 2026 · 1:41 PM EST

Iambic Therapeutics (IAM) Cash & Equivalents (2024 - 2026)

Analysis

Iambic Therapeutics (IAM) Cash & Equivalents (2024 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 4.89 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 16.91 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 10.77 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 9.55 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - 400.00 Mn
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 7.94 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 13.19 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 6.44 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 1.82 Bn
10 Iambic Therapeutics 63.00 Mn -144.88 Mn - 207.88 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 207.88 Mn
Dec 31, 2025 180.54 Mn
Dec 31, 2024 141.58 Mn
API Access

Iambic Therapeutics Cash & Equivalents API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=IAM&period=max&api_key=YOUR_API_KEY